MX2009003542A - Metodos y composiciones con opalescencia reducida. - Google Patents

Metodos y composiciones con opalescencia reducida.

Info

Publication number
MX2009003542A
MX2009003542A MX2009003542A MX2009003542A MX2009003542A MX 2009003542 A MX2009003542 A MX 2009003542A MX 2009003542 A MX2009003542 A MX 2009003542A MX 2009003542 A MX2009003542 A MX 2009003542A MX 2009003542 A MX2009003542 A MX 2009003542A
Authority
MX
Mexico
Prior art keywords
ionic strength
aggregates
antibody
modification
solutions
Prior art date
Application number
MX2009003542A
Other languages
English (en)
Inventor
Pilarin Elizabeth Nichols
Donna Lorriann Luisi
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of MX2009003542A publication Critical patent/MX2009003542A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen métodos para reducir la apariencia opalescente de una preparación proteínica que modifica la fuerza iónica de la preparación, así como composiciones, por ejemplo, composiciones farmacéuticas, de una proteína concentrada con una opalescencia disminuida. También se describen métodos de purificación que monitorizan y/o reducen las concentraciones de sal durante las etapas seleccionadas.
MX2009003542A 2006-10-12 2007-10-12 Metodos y composiciones con opalescencia reducida. MX2009003542A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85165106P 2006-10-12 2006-10-12
PCT/US2007/021904 WO2008045563A2 (en) 2006-10-12 2007-10-12 Modification of ionic strength in antibody-solutions to reduce opalescence/aggregates

Publications (1)

Publication Number Publication Date
MX2009003542A true MX2009003542A (es) 2009-04-15

Family

ID=39205011

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003542A MX2009003542A (es) 2006-10-12 2007-10-12 Metodos y composiciones con opalescencia reducida.

Country Status (12)

Country Link
US (1) US7744890B2 (es)
EP (1) EP2076287A2 (es)
JP (1) JP2010506839A (es)
KR (1) KR20090069330A (es)
CN (1) CN101522219A (es)
AU (1) AU2007308145A1 (es)
BR (1) BRPI0719250A2 (es)
CA (1) CA2665423A1 (es)
IL (1) IL197778A0 (es)
MX (1) MX2009003542A (es)
RU (1) RU2009111138A (es)
WO (1) WO2008045563A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009003542A (es) 2006-10-12 2009-04-15 Wyeth Corp Metodos y composiciones con opalescencia reducida.
EP2020240A1 (en) * 2007-07-30 2009-02-04 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Methods and substances for the treatment of Alzheimer's
KR20110039218A (ko) 2008-06-30 2011-04-15 노보 노르디스크 에이/에스 항-인간 인터루킨-20 항체
CN102395597A (zh) * 2009-03-11 2012-03-28 惠氏有限责任公司 纯化小模块免疫药物蛋白的方法
US8454956B2 (en) 2009-08-31 2013-06-04 National Cheng Kung University Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
US20130004976A1 (en) * 2009-12-25 2013-01-03 Sekisui Medical Co., Ltd. Human insulin assay and assay reagent
SI3409289T1 (sl) 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
SG10201502587SA (en) 2010-03-01 2015-06-29 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
US20130136733A1 (en) 2010-05-28 2013-05-30 Novo Nordisk A/S Stable Multi-Dose Compositions Comprising an Antibody and a Preservative
US9221904B2 (en) 2012-07-19 2015-12-29 National Cheng Kung University Treatment of osteoarthritis using IL-20 antagonists
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US8852588B2 (en) 2012-08-07 2014-10-07 National Cheng Kung University Treating allergic airway disorders using anti-IL-20 receptor antibodies
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
TWI650125B (zh) * 2016-05-19 2019-02-11 長弘生物科技股份有限公司 用於延緩肺纖維化之發病及/或治療肺纖維化之藥劑
ES2974961T3 (es) 2016-08-18 2024-07-02 Regeneron Pharma Ensayo para determinar la capacidad de autoasociación de una proteína usando espectroscopía de autointeracción de nanopartículas dependiente de la concentración
CN107236038B (zh) * 2017-06-20 2020-11-27 华兰生物工程股份有限公司 微晶纤维素提高蛋白质澄清度的方法及其产品和应用
JP7233980B2 (ja) * 2019-03-08 2023-03-07 キオクシア株式会社 粒子計測方法及び検出液

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) * 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
US4399216A (en) * 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) * 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) * 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4396608A (en) * 1981-08-24 1983-08-02 Cutter Laboratories Intravenously injectable immune serum globulin
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4510245A (en) * 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5168062A (en) * 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) * 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8628104D0 (en) * 1986-11-25 1986-12-31 Connaught Lab Pasteurization of immunoglobin solutions
EP0832981A1 (en) * 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
WO1989007947A1 (en) 1988-03-04 1989-09-08 Cancer Research Campaign Technology Limited Improvements relating to antigens
EP1892296A1 (en) 1988-09-02 2008-02-27 Dyax Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5549892A (en) * 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
JPH0396383A (ja) 1989-09-08 1991-04-22 Riso Kagaku Corp 画像形成装置
DK0939121T4 (da) 1989-09-12 2008-02-04 Ahp Mfg B V TNF-bindende proteiner
US5633076A (en) * 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE185601T1 (de) 1990-07-10 1999-10-15 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DK1279731T3 (da) 1991-03-01 2007-09-24 Dyax Corp Fremgangsmåde til udvikling af bindende miniproteiner
DE69233367T2 (de) 1991-04-10 2005-05-25 The Scripps Research Institute, La Jolla Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE122004000008I1 (de) * 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US6607884B1 (en) * 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
JPH09502089A (ja) * 1993-08-27 1997-03-04 ダナ−ファーバー キャンサー インスティチュート インコーポレイテッド ナチュラルキラー細胞特異性抗原およびこの抗原を識別する抗体
US5827690A (en) * 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5516964A (en) * 1994-01-21 1996-05-14 Sun Company, Inc. (R&M) Hydrocarbon isomerization using solid superacid catalysts comprising platinum metal
ES2304786T3 (es) 1995-04-27 2008-10-16 Amgen Fremont Inc. Anticuerpos anti-il-8 humanos, derivados a partir de xenoratones inmunizados.
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
PT859841E (pt) * 1995-08-18 2002-11-29 Morphosys Ag Bibliotecas de proteinas/ (poli) peptidos
GB9524973D0 (en) * 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
WO1998024893A2 (en) * 1996-12-03 1998-06-11 Abgenix, Inc. TRANSGENIC MAMMALS HAVING HUMAN IG LOCI INCLUDING PLURAL VH AND Vλ REGIONS AND ANTIBODIES PRODUCED THEREFROM
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
JP2002507117A (ja) * 1997-06-04 2002-03-05 オックスフォード・バイオメディカ・(ユーケイ)・リミテッド ベクター
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
EP0917879B1 (de) * 1997-11-22 2002-07-17 Boehringer Mannheim Gmbh Verbessertes Verfahren zur Stabilisierung von Proteinen
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
ES2421736T3 (es) * 1998-06-09 2013-09-05 Csl Behring Ag Procedimiento para la preparación de inmunoglobulinas para administración intravenosa y otros productos inmunoglobulínicos
GB2347932B (en) 1998-11-18 2003-05-07 Oxford Biomedica Ltd Vectors for the delivery of 5T4 antigen
JP2002534959A (ja) 1998-12-08 2002-10-22 バイオベーション リミテッド 免疫原性タンパク質の改変方法
US6939545B2 (en) * 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
US7307161B1 (en) * 1999-04-28 2007-12-11 Genetics Institute, Llc Human Gil-19/AE289 polynucleotides
CA2391925A1 (en) 1999-11-18 2001-05-25 Oxford Biomedica (Uk) Limited Antibodies
ATE279442T1 (de) 2000-02-24 2004-10-15 Univ St Louis Humanisierte antikörper, die amyloid beta peptid sequestrieren
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7638604B2 (en) * 2001-02-23 2009-12-29 Genetics Institute, Llc Monoclonal antibodies against interleukin-22
ES2437875T3 (es) 2001-04-30 2014-01-14 Eli Lilly And Company Anticuerpos humanizados que reconocen el péptido beta-amiloide
ATE409047T1 (de) 2001-04-30 2008-10-15 Lilly Co Eli Humanisierte antikörper
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
BRPI0309868B8 (pt) * 2002-05-02 2021-05-25 Wyeth Corp métodos de preparação de uma composição de reduzida fração conjugada inferior
GB0215287D0 (en) * 2002-07-02 2002-08-14 Oxford Biomedica Ltd 5T4 antigen expression
US7261893B2 (en) * 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
BRPI0403964B8 (pt) * 2003-04-04 2021-05-25 Genentech Inc formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
SV2007002227A (es) * 2004-09-10 2007-03-20 Wyeth Corp Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina ref. 040000-0317637
MX2009003542A (es) 2006-10-12 2009-04-15 Wyeth Corp Metodos y composiciones con opalescencia reducida.

Also Published As

Publication number Publication date
WO2008045563A9 (en) 2008-08-14
RU2009111138A (ru) 2010-11-20
BRPI0719250A2 (pt) 2015-06-16
US20080154023A1 (en) 2008-06-26
CA2665423A1 (en) 2008-04-17
EP2076287A2 (en) 2009-07-08
AU2007308145A1 (en) 2008-04-17
WO2008045563A3 (en) 2008-06-19
WO2008045563A2 (en) 2008-04-17
KR20090069330A (ko) 2009-06-30
CN101522219A (zh) 2009-09-02
IL197778A0 (en) 2011-08-01
JP2010506839A (ja) 2010-03-04
US7744890B2 (en) 2010-06-29

Similar Documents

Publication Publication Date Title
MX2009003542A (es) Metodos y composiciones con opalescencia reducida.
MX2007008790A (es) Pirazolo piridinas sustituidas, composiciones que las contienen, metodo de produccion de las mismas, y su uso.
EA200801460A1 (ru) Рекомбинантные моновалентные антитела и способы их получения
WO2010034032A3 (en) Methods for preparing purified polypeptide compositions
PH12013502192A1 (en) Antibodies against human angiopoietin 2
WO2007131072A3 (en) Hydrolytically-resistant boron-containing therapeutics and methods of use
WO2008070692A8 (en) Bicyclic compounds and use as antidiabetics
WO2010065709A3 (en) Hydroxamic acid derivatives, preparation and therapeutic uses thereof
WO2009002947A3 (en) Compounds and peptides that bind the trail receptor
TW200732340A (en) Novel forms of tiotropium bromide and processes for preparation thereof
WO2008132229A3 (en) Highly concentrated insulin solutions and compositions
WO2009130198A3 (en) Hyperglycosylated human coagulation factor ix
HK1123733A1 (en) Viral hepatitis treatment
NO20091509L (no) Substituerte tetrahydropyrrolopyrazinforbindelser med affinitet KCNQ2/3 K+ kanal og anvendelse derav i medikamenter
MX2007013084A (es) Pirrolopiridinas sustituidas, composiciones que las contienen, proceso de fabricacion y utilizacion.
WO2008048589A3 (en) Compounds and methods for treatment of hcv
PL1969127T5 (pl) Metoda wytwarzania biologicznie czynnych białek zależnych od witaminy K metodami rekombinacji
AU2009331669A8 (en) Dihydropyridone amides as P2X7 modulators
WO2009090237A3 (en) Fungicide hydroximoyl-tetrazole derivatives
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
EP2320740A4 (en) PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR PRODUCING LOW IMPURITY CONCENTRATIONS THEREOF
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
JO2721B1 (en) Derivatives of artemisia plant and its preparations and therapeutic applications
EA200701648A1 (ru) Замещённые пирролы и имидазолы, содержащие их композиции, способ получения и применение
WO2006088903A3 (en) Pyrazole compounds

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal